A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats

DEMİR ÖZKAY Ü., CAN Ö. D., SAĞLIK B. N., Turan N.

PHARMACOLOGICAL REPORTS, vol.69, no.6, pp.1349-1356, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 6
  • Publication Date: 2017
  • Doi Number: 10.1016/j.pharep.2017.06.009
  • Journal Name: PHARMACOLOGICAL REPORTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1349-1356
  • Keywords: Acetylcholinesterase, Molecular docking, Elevated plus maze test, Morris water maze test, Active avoidance test, GAMMA-SECRETASE INHIBITORS, POTENTIAL ANTIDEMENTIA DRUG, N-ARYLSULFONYL PIPERIDINES, ALZHEIMERS-DISEASE, INTRACEREBROVENTRICULAR STREPTOZOTOCIN, OXIDATIVE STRESS, CHOLINESTERASE ACTIVITY, INDUCED NEUROTOXICITY, AMYLOID AGGREGATION, MEMORY IMPAIRMENT
  • Anadolu University Affiliated: Yes

Abstract

Background: Acetylcholinesterase (AChE) inhibitors are frequently prescribed to mitigate the cognitive decline in Alzheimer's disease. Thus, we investigated the possible efficacy of the AChE inhibitor 2-[(6-Nitro-2-benzothiazolyl) amino]-2-oxoethyl4-[2-(N, N-dimethylamino) ethyl] piperazine-1 carbodithioate (BPCT) in a streptozotocin (STZ)-induced Alzheimer's disease model (SADM).